Privacy versus confidentiality
Imagine that two pharmacist colleagues meet at a local restaurant. While waiting to be seated, they begin conversing about a patient for whom they have been caring. Coincidentally, others in the vicinity, who know the patient in question, overhear the conversation. Contrast this scenario with that of a pharmacy technician who decides to access the medication profiles of several celebrities through her chain pharmacy's computer system. In both instances, patient data are revealed; however, a violation of confidentiality has occurred in the former case and a violation of privacy has occurred in the latter case.
Although we tend to use them interchangeably, a difference exists between privacy and confidentiality. Beauchamp and Childress 2 provide the following description: "When others gain access to such protected information without our consent, we sometimes describe their access as an infringement of confidentiality and at other times as an infringement of privacy. The difference is this: An infringement of X's confidentiality occurs only if the person to whom X disclosed the information fails to protect that information or deliberately discloses it to someone without X's consent. A person who sneaks into a hospital record room or breaks into a hospital data bank, despite appropriate protections, would be accused of a violation of privacy rather than a violation of confidentiality." "Privacy relates to patients' rights to protect information about themselves." 3 As health professionals, we often violategenerally with permission-a patient's privacy because we have access to his or her medical record. The patient has abdicated to us some of his or her privacy so that we can effectively care for them. As Justice 4 notes, "A very serious problem arises when there is a breach of privacy. ... Remember that a breach of confidentiality involves information over which one has been granted authority. It is quite different if no such authority exists.
To view information about a patient when you have no authority (situational or otherwise) to do so is a breach of privacy, and to disseminate that information is unforgivable." We only violate patient confidentiality when we blatantly or carelessly reveal medical information to others without the consent of a patient. 
Establishing the context
Patient privacy has become an important ethical/legal issue in contemporary medical practice. The National Committee for Quality Assurance (NCQA) and the Joint Commission (formerly the Joint Commission on Accreditation of Healthcare Organizations) note that "growing public mistrust about the privacy of personal information presents a serious threat to health care." 1 In a joint report, Protecting Personal Health Information: A Framework for Meeting the Challenges in a Managed Care Environment, published nearly a decade ago, the two organizations warn that "patients who are worried about the privacy of sensitive personal and medical information may withhold information from health care professionals, increasing the risk of misdiagnosis and inadequate or inappropriate treatment." 5 The issues and recommendations addressed in the report include the following: n Dealing with consent in an evolving health care delivery and financing system. All disclosure of patient information must be done, unless required by law, with the informed consent of the patient, including with whom the information will be shared and for what purposes. n Ensuring accountability. All managed care organizations (MCOs) should develop policies for the handling of patient information, including procedures to ensure compliance. n Educating about policies, practices, rights, and responsibilities. MCOs should inform patients about the handling of confidential information, including storage and dissemination, and provide opportunities for patients to review and comment about their records. n Using technology as a solution. MCOs should use information systems that maximize the protection of patient records. n Providing legislative support. Clear regulatory guidelines which are consistent across jurisdictions should exist for gaining access to patient records. n Guiding research. MCOs should ensure the confidentiality of patient records shared with investigators for research purposes. 5 These recommendations predated the current HIPAA (Health Insurance Portability and Accountability Act of 1996) world in which we live that formally codified patient confidentiality; however, the issues are as pertinent today as when they were initially released. Current NCQA Standards and Guidelines for Managed Care Organizations focused on quality management and improvement, and members' rights and responsibilities incorporated expectations with regard to privacy and confidentiality, including ensuring the confidentiality of patient records. 6 
Ethical principles and moral rules
Today, virtually every school of pharmacy, medicine, and nursing requires coursework in the basics of biomedical ethics. Given the myriad of ethical issues facing health professionals, a basic grounding in ethical principles and moral rules is essential. For practitioners who completed their studies before the widespread inclusion of ethics into the curricula, opportunities for continued professional development in this area are available.
Several ethical precepts provide a good starting point for examining the complicated issue of patient privacy. The moral rule of confidentiality and its relationship to privacy has been discussed. The principle of autonomy and rule of informed consent are also applicable and provide guidance. A brief primer for each is provided below.
Principle of autonomy
The principle of autonomy-a fundamental ethical right to selfdetermination-states that an individual should have liberty of thought, choice, and action. An individual's autonomy cannot be justifiably overridden unless one of two conditions exists: weak paternalism or the harm principle. Weak paternalism involves overriding one's autonomy when the individual is not autonomous or minimal intervention is necessary to determine if the individual is autonomous; the patient's rationality is in question. The harm principle may be justifiably invoked to violate one's autonomy if, in the exercise of that autonomy, harm may come to others.
Respect of patient confidentiality is an application of respect of patient autonomy. Patients have a right to expect that health professionals will keep medical information private, regardless of whether that request is made explicitly by the patient. In doing so, health professionals honor the autonomous wish of their patients to restrict access to patient medical portfolios. This obligation on the part of health professionals even extends to those instances in which they would deem it appropriate and/ or necessary to divulge confidential information to others; if the patient objects to such disclosure, the health professional is ethically obligated to comply.
Rule of informed consent
Informed consent is a logical extension of the principle of autonomy in several respects. The rule of informed consent requires full disclosure to a patient and their voluntary consent before initiating any medical action (e.g., surgery, emergency treatment). By ensuring that informed consent is obtained, health professionals demonstrate their respect for patient autonomy. Failure to meet any of the elements of informed consent (disclosure, understanding, competence, voluntariness, and consent) violates patient autonomy.
One of the elements of informed consent (competence) requires patients to be rational in order to provide their consent. Consequently, individuals who lack the ability to make an autonomous decision (e.g., minor children, patients suffering from severe mental illness) are likewise unable to provide informed consent. Once an individual is determined to be capable of acting autonomously, another element of informed consent, volun-review Go to www.pharmacist.com and take your test online for instant credit. review tariness, must be ensured. Rational, fully informed individuals must have the capacity to make decisions about their care and treatment unencumbered by overt or subtle acts of coercion by health professionals. If this is not the case, an individual's autonomous right to self-determination would be violated.
Like informed consent, the rule of confidentiality can be viewed as an application of the principle of autonomy. As discussed above, by keeping medical information private, the health professional respects a patient's autonomous right to confidentiality. Like autonomy, confidentiality may be violated if a patient is not autonomous (weak paternalism) or if a potential of harm to others exists (harm principle). Consider the following practical examples. A pharmacist who is caring for a patient with severe Alzheimer's disease and is unsure that her medication counseling is understood by the patient may also choose to share the information with the patient's caregiver; weak paternalism is applied in this scenario. The harm principle may be applicable if, for example, a pharmacist is aware of a patient with epilepsy who has chosen not to take his medication as prescribed. This would be especially pertinent in the case of an individual in whom a seizure may place others at direct risk (e.g., bus driver, airline pilot).
Confidentiality, from an ethical perspective, represents the cornerstone of a patient's right to privacy of his/her medical information. From a practical perspective, adherence to patient confidentiality and respect for patient autonomy can result in difficult ethical scenarios. For example, beyond a hospitalized patient's physician and the nurses caring for him/her, who should have access to the patient's medical records? Should the ethical criteria be "sufficient need?" What about health professionals in training (e.g., medical residents, student pharmacists)? Patients generally choose their physician but not others caring for them (e.g., nurses, pharmacists); must patients approve access to their records by these individuals?
Legal principles
The laws and regulations governing patient privacy vary by state; a full discussion of these laws and regulations is beyond the scope of this report. As a result, a brief description of federal statutes and regulations, focusing primarily on HIPAA, appears below.
HIPAA was not the first federal legislation addressing patient privacy. The Privacy Act of 1974 protects health information collected by federal agencies. Federal regulations protect the privacy of alcohol and drug abuse patient records. The Department of Health and Human Services Policy for Protection of Human Subjects shields the records of individuals involved in research trials. 7 HIPAA is the most recent federal legislation addressing patient privacy. The law and its regulations prevent release of patient information to anyone not authorized to have the information or to have a need to know the information. The regulations apply to anyone who handles patient information. Individuals are liable for unauthorized release of confidential information whether unintended or intentional. Authorized use of patient information includes patient care, payment, and operations of the health care providers' organization. 3 Health care providers, however, are required to obtain written permission even for authorized uses, including to whom the information is being disclosed and the manner in which it is being used. 8 Any other use must be disclosed to patients and documented by the provider. Under HIPAA, patients also have the right to access their medical records and make corrections as necessary. 3, 8 The final set of HIPAA regulations, Standards for Privacy of Individually Identifiable Health Information, went into effect in April 2001. In announcing the regulations, the Bush Administration added that guidelines for implementation would be issued and modifications considered as needed to ensure quality of patient care. 8, 9 The HIPAA regulations affect pharmacy in two primary ways. First, pharmacists must ensure that patient consent is obtained and documented. Second, pharmacies must reaffirm their commitment to patient privacy in all business practices. 8 More specifically, HIPAA requires that pharmacies formally identify who within the organization has access and under what circumstances; pharmacies must clearly articulate that they have made every effort to limit access to confidential information only to situations in which it is necessary. 10 The stringent nature of the HIPAA regulations has caused some to speculate that they are better at ensuring confidentiality than ensuring that patients receive the best care possible. For example, discussion regarding a patient and their medications that should occur in the normal course of caring for a patient may not take place because of fear among caregivers of sharing confidential medical information with colleagues. 10 
Health information trustee
Some have suggested that protecting patient records from unauthorized access and use might best be accomplished through the use of a health information trustee. The trustee could be a health plan, data management company, actuarial, or general consulting firm. Health care providers would provide needed information to the trustee, who in turn would remove individually identifying information before disseminating to employers and others. 11 Legislation has recently been introduced in Congress to establish a nationwide health information technology network. The legislation would place patients in charge of their own health information and allow them to restrict select information to various health care providers. 12 
Hospital ethics committees
Recent years have witnessed the growth of hospital or health care ethics committees (HECs). These committees, first mandated by the Joint Commission in 1992, provide institutions with review Go to www.pharmacist.com and take your test online for instant credit. review a consultative body for addressing ethical issues confronting the organization. Committee membership is interprofessional and may include physicians, nurses, pharmacists, and social workers, as well as nonmedical staff such as attorneys, institutional trustees, clergy, and public members. HECs provide a range of functions from prospective services, such as identifying relevant ethical issues and facilitating the resolution of disagreements to retrospective activities, such as formulating policies and guidelines and determining the appropriateness of decisions. 13, 14 Consequently, HECs can provide useful assistance in developing institutional guidelines for handling and disseminating sensitive information.
Law and ethics
Profound conflicts between law and ethics exist throughout health care. Although most laws represent a codification of our moral beliefs as a society, they cannot address every specific situation, nuance, or eventuality. Laws attempt to cover the general circumstances. In pharmacy, for example, dispensing a legend drug without a prescription is illegal. Consider a situation in which a patient's antihypertensive prescription has expired and the prescriber is unavailable to renew it. Most pharmacists would give the patient a few doses to hold them over until a new prescription is obtained; a strong ethical argument can be made in support of this action. Nevertheless, it is still an illegal action and, thus, a legal-ethical conflict results.
Conflicts between law and ethics also exist relative to the privacy of patient records. For example, a court might choose to subpoena medication records of a patient for use in a case, but the patient's pharmacist might believe that they have an ethical obligation to keep the patient's records private. What ought the pharmacist to do? The American Pharmacists Association (APhA) Code of Ethics provides guidance: "A pharmacist promotes the good of every patient in a caring compassionate, and confidential [italics added] manner." 15 However, although a guide to professional behavior, the code carries no federal or state statutory authority. Thus, pharmacists are left with a decision of whether to follow their conscience (exposing themselves to potential legal penalties) or the law.
Beyond patient records, the increased, and welcomed, responsibility placed on pharmacists to manage patient's medication therapy, which is legislated through the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) and, more recently, Medicare Part D, has raised an important legal/ethical issue relative to pharmacist-patient privilege. Craft and McBride 16 first explored this issue relative to OBRA '90 by suggesting that, in many jurisdictions, pharmacists lack the status afforded other health professionals. They note that immunity laws protect professionals from revealing information that is gained during professional communications from court orders and subpoenas. They also ensure that patients can share confidential information with a health professional without concern that the information will be shared with others. Privilege is yet another example of a potential conflict between law and ethics. Although the pharmacist may feel ethically obligated to withhold information, even in the face of action by the court, they may lack the legal protection to do so.
Medical consumerism
Patients today have much different expectations about their care compared with patients even a generation ago. In the past, it was not unusual to see patients following "doctor's orders" with little question; the doctor "knew best." Such is not the case with most contemporary patients, who have become true consumers of medical care. Patients expect to be asked, not told; they expect to have choices presented to them; and they expect their wishes to be followed.
The growing trend of medical consumerism has important implications for patient privacy. When the HIPAA regulations are applied in an environment where medical consumerism dominates, physicians, pharmacists, and other health professionals must be more cognizant than ever of patient wishes relative to their medical records. Patients expect to be able to determine who has access to their records and deny access as they wish. The latitude health professionals may have taken in the past regarding access has been replaced by careful attention to record distribution, even among those with a legitimate right to know.
Impact of technology
The age of computerization has revolutionized American medical practice. The current generation of health professional students and practitioners may find it difficult to envision a time in which computers and personal digital assistants (PDAs) did not play a prominent role. Little is done today in medicine that does not involve computers and, increasingly, the use of artificial intelligence.
However, as Waldo l7 suggests, though offering efficiency in health care, computerized medical records threaten patient privacy. "These [threats] include unauthorized access and tampering. Strategies to circumvent potential problems include physical safeguards, technology-based protection measures, and procedures and policies to control data integrity, access and ensure confidentiality."
Computerization has played an especially important role in the practice of pharmacy. McCarthy and Perrolle 18 discussed the ethical impact of computerization in the early 1990s; in the time since, computers have come to play an even more prominent role and the ethical issues they describe have become more pervasive.
In community pharmacy, computers have become the center of the dispensing process. In addition to producing labels and maintaining records, they allow online third-party adjudication, formulary access, and determination of patient copay-review Go to www.pharmacist.com and take your test online for instant credit. review ments. Today's community pharmacy would be hard-pressed to operate without its computer system. Despite the benefits of computerization, as noted by McCarthy and Perrolle, 18 ethical concerns exist. For example, computerization has allowed easy access to patient information among pharmacies. A community chain pharmacy in Maine has easy access to the medication profile of a patient being cared for by another pharmacy in the same chain in California. Moreover, the opportunity for online identity theft made possible by the availability of computerized patient records, especially given the growth of online pharmacies, is an important concern. Therefore, in addition to being worried about the source and quality of medications purchased from potentially disreputable sources, patients must also be concerned about the security of confidential information. Unfortunately, computerized patient records are not the only source of potential breaches. A pharmacy in Texas was cited recently for not shredding confidential patient information, including credit card and Social Security numbers, before placing them in the trash. 19 Similar privacy issues exist in institutional pharmacy. The combined effect of computerization and the growth of multihospital systems have greatly expanded access to patient records. Access to particular databases may be restricted to particular users or departments, but, not uncommonly, unauthorized individuals gain access.
As in other fields, PDAs have come to play a prominent role in the daily work of pharmacists. From the time they complete advanced pharmacy practice rotations as students, pharmacists come to rely on this technological marvel to provide quick access to a range of drug information. However, the widespread use of these devices comes at a potential price relative to the privacy and confidentiality of patient information. Felkey and Fox 20 describe some of the security challenges that have arisen from the ever-expanding use of these devices and offer some methods of ensuring the confidentiality of patient-specific information that may be stored in them.
Third-party interests
In recent years, the number of third parties with access to or interest in accessing patient medical records has grown substantially. Therefore, in addition to traditional medical third parties (i.e., insurers), the influence of family members, pharmaceutical companies, potential employers, and researchers is described below.
Family
Until fairly recently, not a great deal of attention was given to privacy issues with respect to the family. Husbands and wives had ready access to the medical records of their spouse and children; an adult child could, with little question, obtain access to the medication profile of an aging parent. Today, as described, both the legal and ethical climate have changed; questions exist about who should have access. The following examples illustrate these questions. A husband might seek the prescription records of his wife, ostensibly to file an insurance claim, when in actuality he planned to use her history of drug use against her in a child custody case. Just such a case was reviewed by a California appeals court, which supported a lower court's determination that a pharmacy chain "was liable for common law invasion of privacy and confidentiality because [the plaintiff] had notified the company not to release her prescription drug information to her husband." 21 Imagine an adult child of a sickly, wealthy parent attempting, through the use of a patient medication profile, to have her parent deemed "mentally incompetent" for purposes of obtaining control of the parent's financial assets. Both of these scenarios are not uncommon. What then is the ethical obligation of the pharmacist or other health professional in such situations?
The ethical responsibility of a pharmacist to maintain patient confidentiality in a time of changing family structures and values has become more complex. A pharmacist preventing access to medication records to parties unknown to the patient is not sufficient; they must also restrict and/or limit access within the family itself.
Managed care (PBMs and MCOs)
The evolution of managed health care, unlike any other trend in American health care delivery, has had a profound impact on patient privacy. Traditionally, access to patient records was controlled within a small sphere: the patient's physician, pharmacy, and, perhaps, insurance company. Contemporary health care financing has profoundly expanded those who, it can be argued, require access.
Of particular note is the growth and influence of pharmacy benefits managers (PBMs). In the early 1990s, PBMs were just beginning the process of transforming themselves from fiscal intermediaries to true overseers of the drug benefit. Today, PBMs not only process claims but also manage formularies, perform drug use reviews, and design benefit packages. PBMs and insurers have access to extensive information about patients and their medical history. In many instances, non-health professionals view confidential information. Both professional and nonprofessional staff have access to confidential information, not all of which is pertinent to their work as drug benefit managers. Further, because these records are accessed online, the opportunity for inappropriate access and/or misadventures is increased.
Pharmaceutical companies
One might logically question how and why pharmaceutical manufacturers might gain and require access to patient records; their involvement is a relatively new phenomenon. First, a trend emerged in the 1990s for drug companies to vertically integrate by purchasing PBMs. The thought was that by vertically integrat-review Go to www.pharmacist.com and take your test online for instant credit. review ing through owning a PBM, a manufacturer might be able to use such acquisitions to increase drug sales. 22 As the federal watchdog overseeing such mergers, the Federal Trade Commission carefully monitored the number of a manufacturer's products that appeared on its PBM's formulary. Nevertheless, concerns still existed. One executive of a multistate league of health care buyer groups expressed his fear about the drug maker's influence on the composition of a PBM's formulary when the PBM is owned by a pharmaceutical manufacturer. 23 Although 24 worries about the access of patient medication records by manufacturers still exist. For example, marketing companies have established partnerships between community chain pharmacies and pharmaceutical manufacturers to target patients for treatments of specific conditions. The pharmaceutical manufacturer determines the patient group they wish to target (e.g., patients with diabetes). Then, the marketing firm, using computerized data from the pharmacy chains, sends disease-specific promotional materials to patients. Marketing companies have argued that patient confidentiality is maintained because neither they nor the pharmacy chains provide the pharmaceutical manufacturers with access to prescription files. 25 Legal action has been taken against both pharmaceutical manufacturers and chain pharmacies for alleged collaborations in which manufacturers provided pharmacies with screening information that would allow them to directly market drug products to patients. Ironically, legal protections against such activities are based on state laws, not HIPAA, which allows pharmacies and PBMs to provide drug information to patients (commonly refill reminders) that can be funded by manufacturers. 26 Maine and Vermont have passed laws protecting the confidentiality of the prescription-writing habits of physicians; several companies that collect and sell such data have recently challenged the constitutionality of such laws. 27 Beyond the legal questions, ethical concerns abound. Should pharmacies provide information to pharmaceutical manufacturers on patient medical conditions and medications without patient consent? Does it matter whether the information provided is deidentified and in aggregate form? Does HIPAA truly protect the patient information that it was designed to protect? According to the principles of autonomy and confidentiality, patients should consent to the release of such information and be told specifically to whom and for what purpose the information is being released. Just as individuals have the right to tell telemarketers to put them on the "do not call" list, ethically, patients ought to have the same choice.
Another opportunity for drug company access to patient records exists in situations in which the manufacturer requires patients to participate in a company-sponsored monitoring program. In such instances, manufacturers may have access to patient records that, again, may be beyond what is necessary for safe and appropriate monitoring.
Potential employers
When one examines the recent history of employer-based health insurance in the United States, a clear trend emerges: businesses have become focused on the ever-growing costs of providing health care for their employees and the effect that these costs have on their ability to compete in the world market. Of particular concern is the financial effect that a seriously or chronically ill employee can have on a company's finances, especially for a small company. Small businesses with several employees who have accumulated considerable health care expenditures can experience an increase in insurance premiums that are often unsustainable. As a result, either the employee is terminated or the company must cancel its insurance policy. Consequently, employers have a vested interest in the health of potential employees. Any access to the medical information of potential employees by employers is invaluable. Ethically, do they have a right to such information if not volunteered by the patient? This question has received much public discourse recently in relation to access to genetic information. Should an employer (or insurer) have access to genetic screening tests conducted on a potential employee? Might such access be discriminatory in addition to violating patient confidentiality? Brice and Sanderson 28 note concerns that insurers and employers will gain access to the results of genetic testing. They express trepidation that despite a moratorium on the use of these data by the insurance industry, the public may still be uneasy about its security.
Government
In an attempt to control inappropriate prescribing by clinicians and prescription drug abuse, a number of states have initiated prescription monitoring programs. Despite the good intentions of such programs, fears exist about the loss of patient confidentiality, especially for individuals using prescription medications legitimately and appropriately. The Drug Enforcement Administration's Office of Diversion Control has attempted to quell such fears by suggesting that prescription monitoring programs have adequate safeguards in place to protect patient confidentiality. 29 Nevertheless, governmental agencies do have access to these private records without the consent of patients.
Researchers
An important ethical concern relative to privacy is the type of access, if any, that researchers should have to patient records. Researchers often have to review patient records in the course of their work. When this is done prospectively, patient informed consent is more easily obtained. When the investigator is con-review Go to www.pharmacist.com and take your test online for instant credit. ducting a retrospective study, obtaining consent is much more difficult. Even in instances in which individually identifiable information has been shielded, ethical questions arise concerning the appropriateness of access.
Recently, the National Institutes of Health (NIH) released its policy governing its establishment of a central database of human genetic data, to which scientists will contribute and have access. NIH has promised that patient confidentiality will be protected by requiring researchers to remove personally identifying information before adding their genetic code to the database. Further, NIH will require researchers who wish to use the database to agree not to distribute it publicly. The concern is that insurers might gain access to this genetic information and, as noted above, deny coverage to these at-risk patients. 30 Some investigators have protested that the removal of individually identifiable information will adversely affect potential benefits to patients from health care research. 7 Privacy concerns might prevent researchers from contacting a patient. They argue that, should the research yield results that might be beneficial to the patient, they have no way to identify them. As McKenzie notes, "Researchers could use an accessible database to identify patients who are statistically at risk of contracting particular diseases. They could then contact the patient's doctor so that preventive measures could be taken." 31 
Balancing privacy and quality of care
The impact that these restrictions might have on the quality of care is a primary concern cited by those who oppose increasing restrictions to access of patient records. Although removing individually identifying information from medical records is an important step in ensuring patient privacy, in some circumstances, this gap in data, while protecting privacy may in fact impact the quality of care adversely. For example, consider the case of a physician treating an unconscious patient rushed to the emergency department or a patient receiving polypharmacy therapy. In both instances, the health professional's ability to easily access patient records could lead to a more positive outcome. 31 Further, despite the unprecedented time and effort that health care practitioners and organizations spent to ensure HIPAA compliance, violations of the law have led to very few successful prosecutions of alleged perpetrators. 32 
Health professional organization statements and policies
Both organized medicine and pharmacy have come to realize that patient privacy issues are of considerable ethical and legal concern in contemporary health care practice. Consequently, each has issued strong policy statements in recent years. A report by the Ethical Force Program of the American Medical Association's Institute for Ethics states, "Patients should have the right to access and add material to their own medical records and give consent for such information to be shared." The report also recommends "that a local review committee oversee any instance where an individual is unable to obtain consent for the use of information." 33 In 1998, the APhA House of Delegates adopted the following policies: 1. APhA recognizes pharmacists' need for patient health care data and information and supports their access and contribution to patient health records. 2. APhA supports public policies that protect the patient's privacy, yet preserve access to personal health data for research where the patient has consented to such research or where the patient's identity is protected. 3. APhA encourages interdisciplinary discussion regarding accountability and oversight for appropriate use of health information. 34 These pronouncements provide strong reminders to physicians and pharmacists about the need to be vigilant in this area.
Conclusion
Questions of patient privacy and confidentiality are likely to remain at the forefront of health care ethics and law in the coming years. Health professionals, including pharmacists, must ensure that safeguards exist to prevent unauthorized access of patient records (privacy violations) and intentional or inadvertent disclosure (confidentiality violations). Beyond their legal obligations, health professionals have a basic moral obligation to patients to ensure that such breaches do not occur. Patients must feel confident that their records are safe from inappropriate and unapproved disclosure. Only then will patients be able to effectively focus their attention in the appropriate areaworking with their health professional to improve the quality of their life.
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• Explain the moral rule of informed consent, including its five elements.
• Define the principle of autonomy.
• List two ways in which HIPAA impacts pharmacy practice.
• Provide two ways in which technology has impacted patient privacy.
• State two examples of third parties with access to or interest in accessing patient medical records who may threaten patient privacy.
5. The program increased my knowledge in the subject area.
6. The program did not promote a particular product or company.
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Follow-uP
As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey? We leverage the tremendous resources of CVS Caremark to provide our pharmacists limitless possibilities to grow personally and professionally.
We seek only the best pharmacists to join our team and advance the quest to deliver outstanding health care every day. 
Did You Know…
Some things can't be measured by degrees
As the profession of pharmacy becomes more specialized and more demanding, the Board of Pharmaceutical Specialties offers a unique opportunity to demonstrate advanced clinical profi ciency in fi ve major practie areas: Nuclear Pharmacy, Nutrition Support Pharmacy, Pharmacotherapy, Oncology Pharmacy, and Psychiatric Pharmacy. Visit the BPS web site for details. I n our January 2005 column, we shared a report of a 5-month-old boy who nearly died after a cap on a parenteral syringe became lodged in his throat. In that case, a pharmacist had given the boy's mother a parenteral syringe (without the needle) to accurately measure and administer an oral antibiotic suspension to the child.
However, the pharmacist was unaware that the manufacturer had used a small translucent cap on the syringe tip as a protective cover. With the cap intact, the father inserted the syringe into the medical suspension, pulled back the plunger, and the medication flowed into the syringe. To him, the cap appeared to be part of the syringe. When the father placed the syringe containing the medication into the baby's mouth, the cap flew off and became lodged in the baby's airway. The infant was taken to the hospital, and a procedure was performed to remove the cap; however, the child did not survive.
